Leonid Timashev
Stock Analyst at RBC Capital
(1.69)
# 2,231
Out of 4,412 analysts
29
Total ratings
24%
Success rate
-4.91%
Average return
Main Sectors:
Top Industries:
8 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EWTX Edgewise Therapeutics | Maintains: Outperform | $28 → $32 | $16.17 | +97.90% | 5 | Apr 22, 2024 | |
| BHVN Biohaven Pharmaceutical Holding Company | Reiterates: Outperform | $61 | $38.97 | +56.53% | 3 | Apr 9, 2024 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $123 → $128 | $71.71 | +78.50% | 3 | Mar 26, 2024 | |
| PYXS Pyxis Oncology | Reiterates: Outperform | $7 | $4.30 | +62.79% | 2 | Mar 22, 2024 | |
| DSGN Design Therapeutics | Reiterates: Sector Perform | $4 | $3.78 | +5.82% | 7 | Mar 20, 2024 | |
| LEGN Legend Biotech | Reiterates: Outperform | $85 | $45.30 | +87.64% | 6 | Mar 12, 2024 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Outperform | $25 → $31 | $21.99 | +40.97% | 2 | Feb 29, 2024 | |
| NBSE NeuBase Therapeutics | Downgrades: Sector Perform | $240 → $20 | $0.44 | +4,449.59% | 1 | Oct 18, 2022 |
Edgewise Therapeutics
Apr 22, 2024
Maintains: Outperform
Price Target: $28 → $32
Current: $16.17
Upside: +97.90%
Biohaven Pharmaceutical Holding Company
Apr 9, 2024
Reiterates: Outperform
Price Target: $61
Current: $38.97
Upside: +56.53%
Axsome Therapeutics
Mar 26, 2024
Maintains: Outperform
Price Target: $123 → $128
Current: $71.71
Upside: +78.50%
Pyxis Oncology
Mar 22, 2024
Reiterates: Outperform
Price Target: $7
Current: $4.30
Upside: +62.79%
Design Therapeutics
Mar 20, 2024
Reiterates: Sector Perform
Price Target: $4
Current: $3.78
Upside: +5.82%
Legend Biotech
Mar 12, 2024
Reiterates: Outperform
Price Target: $85
Current: $45.30
Upside: +87.64%
NewAmsterdam Pharma Company
Feb 29, 2024
Maintains: Outperform
Price Target: $25 → $31
Current: $21.99
Upside: +40.97%
NeuBase Therapeutics
Oct 18, 2022
Downgrades: Sector Perform
Price Target: $240 → $20
Current: $0.44
Upside: +4,449.59%